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Footnotes 
1. OFF. OF NAT’L DRUG CONTROL POLICY, NATIONAL DRUG CONTROL
STRATEGY 2000 ANNUAL REPORT (2000) at 115–116.  Seventy-four
million Americans have tried an illicit drug at least once in their
lifetime; 2.4 million have tried heroin at least once, 22.1 million
have tried cocaine at least once, and 4.6 million have used crack
at least once.  OFF. OF NAT’L DRUG CONTROL POLICY, DATA
SNAPSHOT–DRUG ABUSE IN AMERICA 1998 (1998) at 32-33. In 1999,
1,254,577 Americans were in federal and state prisons.  OFF. OF
NAT’L. DRUG CONTROL POLICY (March 2001), infra note 2 at 1.  
2. OFF. OF JUSTICE PROGRAMS, U.S. DEP’T OF JUSTICE, CRIME AND JUSTICE
ATLAS 2001 UPDATE (2001) at 5.  The Office of National Drug
Control Policy recently reported the following:
In 1999, approximately 6.3 million adults—3.1% of the
Nation’s adult population—were under correctional super-
vision (that is, incarceration, probation or parole).  Drug
offenders accounted for 21% (236,800) of the State prison
population in 1998, up from 6% (19,000) in 1980, and 59%
(55,984) of the Federal prison population in 1998, up from
25% (4,749) in 1980.  Also, in 1998, an estimated 26%
(152,000) of all inmates under local supervision were
incarcerated for drug offenses. This increase in the drug
offender prison population mirrors the steady increase in
arrests for drug offenses.
OFF. OF NAT’L DRUG CONTROL POLICY, DRUG TREATMENT IN THE
CRIMINAL JUSTICE SYSTEM FACT SHEET (March 2001) at 1.   
3. OFF. OF NAT’L DRUG CONTROL POLICY, supra note 1, at 114.
4. BUREAU OF JUSTICE STATISTICS, SOURCEBOOK OF CRIMINAL JUSTICE
STATISTICS 1999 (2000) at 484.   
5. Id. at 513.   See also NELS ERICSON, SUBSTANCE ABUSE:  THE
NATIONS’S NUMBER ONE HEALTH PROBLEM.(OJJDP Fact—Sheet #17)
(May 2001).
6. OFF. OF NAT’L DRUG CONTROL POLICY, PULSE CHECK:  NATIONAL
TRENDS IN DRUG ABUSE (Summer 1998), at i.
7. DRUG ENFORCEMENT ADMIN. & THE NAT’L GUARD, DRUGS OF ABUSE
(1997) at 13.
8. Id.
9. Id. The DEA estimated that purity levels of heroin in 1981 were
7%, and in 1998 the average purity rate was 41 % nationwide.
Estaban Parra, infra note 18.  The ingestion of heroin either by
smoking or snorting has increased from 55% in 1994 to 71% in
1997.  OFF. OF NAT’L DRUG CONTROL POLICY, supra note 6 at 30.
Drug use in the United States has been cited for thegrowth in American prisons over the past decade.Heroin, once considered a drug to be avoided and
scorned, has had resurgence in use by middle-class youth and
white-collar professionals due to the increased purity of the
drug and the lack of need to use needles for ingestion.
Naltrexone has been used as a method of helping heroin
addicts to end their drug dependency, but such programs have
limitations in their use and effectiveness. This paper is drawn
from an evaluation of a drug treatment program in
Wilmington, Delaware.  The goal of this paper is to review the
factors that lead to successful drug treatment and the limita-
tions on the success of drug treatment that the judiciary
should consider when sentencing drug addicts. 
More than 13 million Americans used an illicit drug at least
once in 1998, and 977,000 Americans classified themselves as
hardcore heroin users in 1999.1 The growth of increased drug
use has impacted the criminal justice system.  “In 1997, over
one third of prison commitments involved drug offenses, com-
pared to only 7% in 1980.  In 1980, about half of all commit-
ments were for violent offenses; by 1997, only about one third
were.”2 In 1999 Americans spent an estimated $63.2 billion
for cocaine, heroin, methamphetamine, and other illicit
drugs.3  The impact of this increased drug use can be seen in
the fact that the number of Americans incarcerated (prison
only) reached more than one million (1,078,542) in 1995 for
the first time in U.S. history.4 According to the Bureau of
Justice Statistics, the percentage of prisoners in federal prison
incarcerated for dugs increased from 57.9% of the total popu-
lation in 1991 to 62.6% in 1997 and the percentage of drug
offenders in state prisons decreased from 21.3% of the total
population in 1991 to 20.7% in 1997.5
“The majority of heroin users are still older, chronic users
who inject the drug.  At the same time, the number of new,
young users who snort or smoke the drug continues to rise.”6
According to the DEA, the “typical heroin user today con-
sumes more heroin than a typical user did just a decade ago,
which is not surprising given the higher purity currently avail-
able at the street level.”7 Historically heroin is taken intra-
venously, subcutaneously (under the skin), or intramuscu-
larly8 but due to the high level of purity (as high as 98%), it
can be snorted or smoked.  The purity of the heroin now
makes heroin snorting possible, and makes heroin more
“appealing to new users because it eliminates both the fear of
acquiring syringe-borne diseases . . . and the historical stigma
attached to intravenous heroin use.”9
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10. OFF. OF NAT’L DRUG CONTROL POLICY, supra note 6 at 4. 
11. New Castle County Police Heroin Alert Task Force, “Heroin:  The
New Serial Killer That Is Stalking Our Children,” presentation
made on Sept. 26, 1998.
12. Supra note 6 at 3. “The hub of the area heroin trade [is in] the
Kensington section of Philadelphia. That’s where many Delaware
addicts go to get [their heroin]. Through the first 10 months of
1998 [there were] 716 arrests for heroin” of which 30 were peo-
ple from Delaware.  Tom Feeney & Esteban Parra (1998). Hooked
on Heroin: Police Sound the Alarm, SUNDAY NEWS JOURNAL, Nov. 29.
1998, at A1.
13. New Castle County Police Heroin Alert Task Force, supra note 11.
14. Feeney & Parra, supra note 12.
15. Id. at A1.
16. Id.
17. DRUG ENFORCEMENT ADMIN. & THE NAT’L GUARD, supra note 7 at
13.
18. New Castle County Heroin Alert Task Force, supra note 11.  DEA
investigations have discovered that heroin sold in Dover and Kent
County originates in New York City. The heroin market in the
U.S. is dominated by two sources, Columbia and Mexico.
Columbian heroin is dominant along the east coast in cities like
Boston, New York City, Newark, N.J., and Philadelphia.
Columbian heroin averages at almost 68% pure, but the
Columbian heroin in Dover has been found in the high 90%
range. The heroin purity rate in Dover has been found to be
higher than in Philadelphia, which is about 80%. The combina-
tion of the high purity rate of heroin in Delaware and the low cost
is blamed for the increase of heroin use in suburban areas in
Delaware. Estaban Parra, Purity Is Part of the Local Problem,
SUNDAY NEWS JOURNAL, Jan. 21, 1999, at A7. The dividing line
between South American (high purity white) and Mexican (lower
purity “black tar”) heroin is the Mississippi River. OFFICE OF NAT’L
DRUG CONTROL POLICY, supra note 2 at 31.  
19. STEDMAN’S MEDICAL DICTIONARY (25th ed.1990).  HAROLD KAPLAN
& BENJAMIN SADOCK, COMPREHENSIVE TEXTBOOK OF PSYCHIATRY (6th
ed. 1995).  Joseph Ternes & Charles O’Brien, The Opioids:  Abuse
Liability and Treatment for Dependence, in ADDICTION POTENTIAL OF
ABUSED DRUGS AND DRUG CLASSES (Barry Stimmel ed., 1990) 
20. Kaplan & Sadock, supra note 19 at 844.
21. Id. “Heroin crosses the blood-brain barrier more rapidly than
morphine and produces greater euphoric effects when given in
equal doses. Once in the brain, heroin is hydrolyzed to morphine
almost immediately.”  Id. at 31.  Both heroin and morphine are
derivatives of opium and as such are considered opiates.
Opiates attach to the opioid receptors of the brain and produce
similar euphoric and pleasure reactions to natural occurring pain
suppressants in the brain (endorphins and enkephalins) which
also attach to the opioid receptors of the brain. SUBSTANCE ABUSE
AND MENTAL HEALTH SERVICES ADMIN. (SAMSHA), NALTREXONE AND
ALCOHOLISM TREATMENT:  TREATMENT IMPROVEMENT PROTOCOL
(TIP) (1998), series #28 at 28.  Both endogenous opioids (endor-
phins and enkephalins) and exogenous opiates (heroin and mor-
phine) act as neurotransmitters that transfer information through
the nervous system. In the case of opioid neurotransmitters, the
information is pain relief and pleasure responses.  See infra note
32 for discussion on the cycle of addiction theory.
22. Kaplan & Sadock, supra note 19 at 844.
23. Id.
24. Id. See also, infra note 25, and Robert Greenstein et al., Methadone
and Naltrexone in the Treatment of Heroin Dependence, 7
PSYCHIATRIC CLINICS OF NORTH AMERICA, 671 (1984). 
In Newark, Delaware, the purity of heroin has been found
to range from 20% to 90%.10 The New Castle County Police
have reported that purity levels have been found to be as high
as 97% in Dover, Delaware.11 According to the Office of
National Drug Control Policy, Newark, Delaware sources
report that there has been a “‘definite increase in teenage
users’. . . dealers, some from nearby Philadelphia, are making
a clear attempt to establish a new market.  For example, by
encouraging young females to begin use, dealers hope to
attract older male users.  In that area, users start at around 13,
and the source reports that there are ‘chronic’ users aged 15 -
17.”12 It has recently been reported that between 1993 and
1995, 88% of new heroin users were between the ages of 12 to
25 years old.13 The “average age of addicts seeking treatment
is getting younger.   In 1993, only 17.2 percent of heroin
addicts who reported for treatment were 24 or younger.  By
1997, the percentage had climbed to 31.7 percent.”14 The
number of people who are treated for heroin addiction in
Delaware has increased from 336 in 1991 to 1,767 in 1997, an
increase of 426%.15 The impact of the increase in heroin usage
can be seen in the number of heroin-related deaths.  Deaths
related to heroin have increased from 14 in 1991, to 29 in
1997.16 The national average of heroin purity is 35%.17 The
average purity level for heroin in Delaware is 85%.18
In an effort to deal with the growing heroin use problem in
Delaware, SODAT-Delaware, Inc., received more than
$1,650,000 over a three-year period (1995–1997) to imple-
ment an intensive outpatient therapy program (SNAP), which
uses the blocking medication nal-
trexone to assist heroin addicts in
their attempts to discontinue the
use of heroin and other drugs and
to promote pro-social behavior
with no new criminal arrest.
A BRIEF REVIEW ON THE USE
OF HEROIN AND
NALTREXONE 
Heroin is a semi-synthetic
derivative of opium prepared from morphine.19 Heroin was
first introduced into medicine in 1898 and was used as a pain
medication until the addictive nature of opioids in general was
found.20 Heroin is classified as a narcotic due to its ability to
produce mood and behavior changes, potential for dependence
and tolerance following continued use, and derivation from
opium.21 In 1914 the Harrison Act was passed, which is
“interpreted as excluding the provision of opioids to addicts as
a legitimate medical use.”22 Although the use of opiates was
illegal, “heroin addiction persisted and its prevalence rose fol-
lowing World War II [and by] the early 1960’s [many recom-
mended] remedicalizing heroin distribution as a way to reduce
crime associated with heroin addiction.”23
With the increase of heroin addiction in the U.S. Military
during the Vietnam War and in society as a whole, federal
funds were expended for both research and treatment of heroin






ages of 18 to
25 years old.
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25. Kaplan & Sadock, supra note 19 at 844.  For a review of early
research on naltrexone in heroin addiction, see Richard Resenick
et al., Narcotic Antagonists in the Treatment of Opioid Dependence:
Review and Commentary, 20 COMPREHENSIVE PSYCHIATRY, 116
(1979). See also, DEMETRIOS JULIUS & PIERRE RENAULT, NARCOTIC
ANTAGONISTS: NALTREXONE (National Institute on Drug Abuse
Research Monograph # 9, 1976),which encompasses 25 articles
on naltrexone treatment studies for the first half of the 1970s that
were funded by the National Institute on Drug Abuse, U.S.
Department of Health, Education, and Welfare.
26. Robert Greenstein et al., supra note 24 at 675; Joseph Ternes &
Charles O’Brien, supra note 17 at 43.  See also, Vis Navartnam et
al., Determination of Naltrexone Dosage for Narcotic Antagonist
Blockade in Detoxified Asian Addicts, 34 DRUG AND ALCOHOL
DEPENDENCE, 231 (1994), which found naltrexone to be effective
in blocking the physiological and psychological effects of heroin
for at least 48 and 72 hours, respectively.  Opioid antagonists like
naltrexone “block opioid receptors and reverse the effects of
endogenous opioid peptides as well as exogenous opiates [and it
is theorized that] these agents may prevent the reinforcing effects”
of consumption of heroin. SAMHSA, supra note 21 at 32.  
27. DRUG FACTS AND COMPARISONS (1998) at 3579. See also, Joseph
Volpicelli, Naltrexone and the Treatment of Alcohol Dependence, 18
ALCOHOL HEALTH & RES. WORLD: JOURNAL NAT’L INST. ON ALCOHOL
ABUSE AND ALCOHOLISM 272 (1994). 
28. Kaplan & Sadock, supra note 19 at 857.  See, Abraham Wikler,
Dynamics of Drug Dependence: Implications of a Conditioning
Theory for Research and Treatment, 28 ARCHIVES OF GENERAL
PSYCHIATRY 611 (1973), and Wikler, Conditioning Factors in Opiate
Addiction and Relapse, in NARCOTICS (Daniel Wilder and Gene
Kassenbaum eds., 1965) at 85 for early work on the use of nar-
cotic antagonists for treating heroin addiction.   See also, Karen
Allen, Essential Concepts of Addiction for General Nursing Practice,
33 NURSING CLINICS OF NORTH AMERICA 1.
29. Kaplan & Sadock, supra note 19 at 857.  See also, Charles O’Brien
et al., Use of Naltrexone to Extinguish Opioid-Conditioned
Responses, 45 J. CLINICAL PSYCHIATRY 53.
30. See Avram Goldstein, Naltrexone in the Management of Heroin
Addiction: Critique of the Rationale, in NARCOTIC ANTAGONISTS:
NALTREXONE (National Institute on Drug Abuse Research
Monograph # 9) (Demtrios Julius & Pierre Renault eds., 1976)
158, 159.  See also, Richard Resinick, et al., supra note 25, and
Richard Resnick & Elaine Schuyten-Resnick, A Point of View
Concerning Treatment Approaches with Narcotic Antagonists, in
NARCOTIC ANTAGONISTS: NALTREXONE 84 (1976).
31. Avram Goldstein, supra note 30 at 159.  “Relapse to heroin use in
abstinent ex-addicts is rarely cogitated and planned in advance.
Conditioned abstinence (‘craving’) can be elicited by accidental
encounters with active addicts . . . or other major stress.” Id. On
the issue of behavior, Goldstein noted that humans have the abil-
ity to “anticipate consequences and to modify our behavior
accordingly. In this connection, the observation that naltrexone
can diminish ‘craving’ is entirely understandable, since ‘craving’ is
generally elicited by the possibility of obtaining a drug rather than
by its unavailability. It follows from this analysis that naltrexone
can only work if the patient understands how it works and
believes that it will work.” Id. at 159–160.  Goldstein also asserted
that because the patient knows that the naltrexone will block the
affects of heroin and thus taking the drug will be futile, “it is not
surprising that many subjects taking naltrexone may not use
been developed to treat heroin
addicts.  One of the treatment
methods developed over the
past 25 years involves the use of
long-acting opioid antagonists
for heroin addicts.25 Antagonist
treatment methods differ from
substitution (maintenance)
treatment programs in that the
antagonist programs use med-
ication to eliminate an addic-
tion.  Substitution treatment
methods use one drug,
methadone, for example, as a
replacement for another drug,
heroin.  The SNAP program was
an antagonist treatment pro-
gram that used the opioid
antagonist naltrexone, which
“blocks or reverses the physiologic and psychological effects of
opioids by binding opiate receptors” in the brain.26
Naltrexone “prevents or reverses opioid effects [and] will pre-
cipitate abstinence . . . in narcotic addiction.”27 The use of nal-
trexone is based on “the assumption that classically conditioned
withdrawal symptoms and operantly reinforced drug seeking
behaviors contribute to high relapse”28 in heroin addicts. 
Theoretically, by blocking the euphoric effects of
opioids, treatment with antagonists would lead to
the extinction of operantly reinforced drug seeking;
by preventing the reestablishment of physical
dependence, treatment with antagonists also leads
to the eventual extinction of conditioned with-
drawal phenomena.  Recently, . . . empirical and lab-
oratory observations [show] patients taking nal-
trexone experience less craving in the presence of
opioid-related cues, presumably because, on a cog-
nitive basis, they are aware that they are unable to
experience the opioid effects.29
Early studies and theoretical use of naltrexone proposed that
naltrexone would be effective in dealing with impulsive and
compulsive heroin use in addicts who are in treatment.30 Early
researchers of heroin addiction recognized that recovering
heroin addicts could recidivate and develop full addiction due
to impulsive heroin use by environmental stimuli.  The stimuli
could be an interaction between the recovering addict and a
friend, whom the addict had a history of heroin use with, or
being in a neighborhood in which heroin is used.  The stimulus
causes a craving for the heroin that could cause readdiction.
Goldstein explained that “naltrexone can protect against impul-
sive use and can prevent the consequences of impulsive use.
The protective medication, [the naltrexone], is taken at a time
when motivation [to end the addiction] is high, then later, if
circumstances arise that would typically lead to use the agonist
drug [heroin], there is a strong reason to avoid that behavior”
because the subject knows the heroin will not have any effect.31
Naltrexone can also aid in the reduction of compulsive addic-
tion.  The cognitive knowledge that the use of the heroin will














not have an effect reduces the obsessing over the craving for the
heroin.  Thus naltrexone will assist the addict in developing
behavior re-enforcers to resist the thoughts and desires for the
drug, in turn reducing compulsive addictive behavior.
Although use of naltrexone has been found to block the
effects of heroin, one of the biggest problems in heroin addic-
tion32 treatment, along with heroin detoxification of addicts, is
low compliance in taking the naltrexone by the addicts and
their high dropout rate.33 Kaplan and Sadock noted that in one
study, “the dropout rate was quite high: 25 percent of subjects
who started treatment dropped out within two weeks; 94 per-
cent stopped by nine months.”34 In a study in Israel, the aver-
age retention rate for program participants was 56.3 days.35
Out of a total of 32 patients, 58 percent completed the pro-
gram.36 Forty percent of the patients dropped out of the pro-
gram within two weeks, and 60% of the patients who dropped
out did so within the remaining ten weeks of the program.37
PROGRAM THEORY DESCRIPTION
The SNAP program was based on the theory that the heroin
addict (once detoxification is completed) will be assisted in end-
ing his or her heroin addiction if medication was provided that
blocked the effects of the heroin.  The heroin-blocking medica-
tion provided was naltrexone.  Naltrexone is an orally adminis-
tered medication, which prevents the uptake and effects of opi-
oid compounds.  Thus, when taking this medication, any person
who uses heroin by any route
will not experience any effects
whatsoever. The naltrexone
protocol was used in conjunc-
tion with intensive outpatient
therapy and therapeutic case
management services.
The general focus of the
SNAP treatment was on
client stabilization, mainte-
nance of a drug-free and
crime-free lifestyle, a recov-
ery-oriented support net-
work, and relapse prevention
education.  The SNAP pro-
gram was designed to provide
a four-phase treatment strat-
egy for heroin addicts over a
12-to-18-month period.
METHODOLOGY
Between October 7, 1993, and July 22, 1998, the SNAP pro-
gram provided 73 participants naltrexone as part of their treat-
ment for heroin addiction.  Data was collected from the case
files of all 73 participants, which included basic demographic
information (age, gender, race), employment status, history of
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receptor blocking pharmacological agents in the battle to reduce
relapse in early recovery.” Id.  See also, D. Colin Drummond.
Theories of Drug Craving, Ancient and Modern, 96 ADDICTION 33
(2000). For a discussion on opiate receptor sites within the brain,
see Roy Wise, Opiate Reward: Sites and Substrates, 13
NEUROSCIENCE AND BIOBEHAVIORAL REVIEW, Summer-Fall 1989, 129,
and Jane Stewart, supra note 31.
33. High dropout rates can be partially explained by the nature of
addiction.  As noted in footnotes 21 and 32, the consumption of
heroin produces a pleasurable experience that can be stronger
than natural pleasurable experiences. The experience in turn pro-
duces chemical reinforcers to the use of heroin. The reduction or
stopping of the behavior (heroin use) produces the chemical rein-
forcers in the brain, which in turn produce craving for the behav-
ior (heroin use). The craving in turn produces the continuation of
the behavior (heroin use). Negative reinforcement and addiction
are achieved. Treatment programs using naltrexone block the
pleasure reaction of opiates and opioids in the brain. But the psy-
chological desire for the heroin and the resulting pleasure from
using the drug causes the person to stop taking the naltrexone in
order to have the heroin have its desired effect. It is here that
treatment modalities like cognitive therapy and group therapy can
have an effect, for therapy addresses the emotional need for the
heroin and how to resist the need.
34. Kaplan & Sadock, supra note 19 at 857.   See also, Emi Shufman
et al., The Efficacy of Naltrexone in Preventing Reabuse of Heroin
after Detoxification, 35 SOCIETY OF BIOLOGICAL PSYCHIATRY 935
(1994).
35. Emi Shufman et al., supra note 34 at 939.  “In this study, 75% of
the patients stayed in the program after 1 month, and 58% com-
pleted the 3 months treatment period.” Id.at 942.
36. Id. at 942.
37. Id. at 939.
heroin to test and verify the protection.” Id. at 159.  For research
showing that heroin addicts will test the blocking ability of nal-
trexone, see infra note 40. For a study looking at impulsive heroin
addicts and self-control, see Gregory Madden et al., Impulsive and
Self-Control Choices in Opioid-Dependent Patients and Non-Drug-
Using Control Participants: Drug and Monetary Rewards, 5
EXPERIMENTS IN CLINICAL PSYCHOPHARMACOLOGY 256 (1997).  For a
study looking at compulsive use of heroin and the opioid recep-
tors and naltrexone, see Jane Stewart, Conditioned and
Unconditioned Drug Effects in Relapse to Opiate and Stimulant Drug
Self-Administration, PROGRESS IN NEUROPSYCHOPHARMACOLOGY &
BIOLOGICAL PSYCHIATRY 591 (1983).
32. In the development of the cycle of addiction, the intake of heroin
leads to an increase in opioid receptor activity. “Once opioid
receptor activity has been primed, more [heroin] is needed to
ensure continued opioid receptor activity. Therefore, a cycle may
ensue during which the desire to increase or recapture feelings of
pleasure or euphoria is translated into cravings for [the heroin].
The loss of control that follows the initial consumption of a rein-
forcing agent [the heroin] may provide the root mechanism for
. . . addictive behavior.”  SAMHSA, supra note 19 at 31–32.  Thus
the use of heroin can have a “priming” for additional use.  The use
of heroin, even a small amount, can effect a release of endorphins
(which produce feelings of pleasure), which in turn increase the
desire for more heroin, which in turn produce more release of
endorphins.   Addiction research has found “that opiates can have
an effect equal to that of having an appetizer before dinner. A
small dose of a substance that effects the opiate receptor sites can
increase the drive to consume more of the same.”  The first inges-
tion of the heroin increases the motivation to have another.
Alfred Turner, Naltrexone: The Magic Bullet for Alcoholism (1995),
available at www.enteract.com/~alturner/neltrexo.html.  “This
appetizer or priming effect provides good reason to look at opiate
The SNAP program












38. See Michael Stark & Barbara Campbell, Personality, Drug Use, and
Early Attrition from Substance Abuse Treatment, 14 AM. J. DRUG &
ALCOHOL ABUSE 475 (1988); Charles O’Brien et al., Clinical
Experience with Naltrexone, 2 AM. J. DRUG & ALCOHOL ABUSE 365
(1975); Steven Sideroff et al., Craving in Heroin Addicts Maintained
on the Opiate Antagonist Naltrexone, 5 AM. J. DRUG & ALCOHOL
ABUSE 415 (1978); Richard Greenstein et al., Naltrexone: A Short-
Term Treatment for Opiate Dependence, 8 AM. J. DRUG & ALCOHOL
ABUSE 291 (1981); Len Derogatic & Nick Melisaratos, The Brief
Symptom Inventory: An Introductory Report, 13 PSYCHOL. MEDICINE
595 (1983); Richard Greenstein et al., Naltrexone: A Clinical
Perspective, 45 J. OF CLINICAL PSYCHIATRY, Sept. 1984, 25; Herbert
Kleber & Thomas R. Kosten, Naltrexone Induction: Psychological
and Pharmacological Strategies, 45 J. OF CLINICAL PSYCHIATRY, Sept.
1984, 29; Forest Tennant et al., Clinical Experience with Naltrexone
in Suburban Opioid Addicts, 45 J. OF CLINICAL PSYCHIATRY, Sept.
1984, 42; Miguel Gutierrez et al., Retention Rates in Two
Naltrexone Programmes for Heroin Addicts in Victoria, Spain, 10
EUR. PSYCHIATRY 183.
39. Charles O’Brien & Richard Greenstein, Treatment Approaches:
Opiate Antagonists, in SUBSTANCE ABUSE: CLINICAL PROBLEMS &
PERSPECTIVES (Joyce Lowenson & Pedro Ruizeds, 1981) 403.
40. Forest Tennant et al., supra note 36; Daniella D’Ippoliti et al.,
Retention in Treatment of Heroin Users in Italy: The Role of
Treatment Type and of Methadone Maintenance Dosage, 52 DRUG &
ALCOHOL DEPENDENCE 167  (1998). See also, George W. Joe et al.,
Recidivism Among Opioid Addicts After Drug Treatment: An Analysis
by Race and Tenure in Treatment, 9 AM. J. DRUG & ALCOHOL ABUSE,
371 (1982-83).
drug abuse, and drug use after the
first ingestion of naltrexone.  
SUMMARY OF FINDINGS
The majority of SNAP partici-
pants were single-male African-
Americans. The median age of
SNAP participants was 31 years
old.  Almost all of the participants
had prior drug histories.  The
majority, 81%, began drug use before the age of 18.  The main
two introduction drugs were alcohol and marijuana.  More
than 70% of SNAP participants used at least one of these drugs
as the first drug in their drug use histories.  The median age for
first drug use was 15, and 14 years old was the mode.
The majority of SNAP patients did not test positive for
drugs while in the program. More than 75% of the participants
remained drug free.  But there was not a corresponding result
in successful treatment by SNAP participants.  The majority of
SNAP participants did not successfully complete the program.
While the majority of participants did not use drugs, only 13%
successfully completed the treatment.  These results may sug-
gest that drug treatment success may not be related to remain-
ing drug free during treatment.  The majority of participants
who entered the SNAP program did so unemployed (52%).  At
time of discharge, the majority of participants were employed
(57.5%).  
Previous drug treatment histories did not provide an
increased chance of successful completion in the SNAP pro-
gram.  Of the 71 SNAP participants who had prior drug treat-
ment histories, 84.5% failed to successfully complete treatment.
As would be expected, the longer participants remained in the
program the higher the rate of program success.  Out of the ten
participants who succeeded in treatment, nine remained in the
program longer than six months.  Conversely, 60.7% of those
who failed to complete treatment remained in the program less
than six months.  The median length of time SNAP participants
remained in the program was almost five months.  
Being married did not prove to be a positive factor in suc-
cessful treatment.  Participants who were married and success-
fully completed treatment accounted for only 6.7% of the mar-
ried SNAP population. Those participants who were single and
successfully completed treatment accounted for 15.8% of the
single SNAP population.  Those who were married and failed to
complete treatment accounted for 93.3% of the married SNAP
population.  Those participants who were single and failed to
complete treatment accounted for 80.7% of the single SNAP
population. Thus, a higher percentage of those who were single
successfully completed treatment than those who were married,
and a higher percentage of those who failed treatment were mar-
ried than those who failed and were single. The data may sug-
gest that there may be an inverse relationship between success-
ful completion and being married.  An alternative theory could
be that these married addicts had unstable marriages or were
married to addicts.  If so, these negative relationships could be
decreasing the opportunity for the SNAP participants to take
advantage of the program and successfully complete treatment.
Being employed was associated with program success.  Those
participants who were employed and successfully completed
treatment accounted for 21% of the employed SNAP population.
Those participants who were unemployed and successfully
completed treatment accounted for 3.4% of the total unem-
ployed SNAP population. Those who were employed and failed
to successfully complete treatment accounted for 76% of the
employed SNAP population. Those participants who were
unemployed and failed to complete treatment accounted for
93% of the unemployed SNAP population.  Thus, a higher per-
centage of those who were employed successfully completed
treatment than those who were unemployed, and a higher per-
centage of those who failed treatment were unemployed than
those who failed and were employed.
The majority of the SNAP patients started to use drugs in
their early teen years.  Longer periods spent using drugs were
associated with failure to complete treatment successfully.  
The SNAP program achieved a 75% negative test for drug use
and 13.7% treatment success rate.   A review of the literature
shows that success rates in naltrexone treatment programs for
heroin addicts can range from 12% to 20%.38 For example,
O’Brien and Greenstein39 note in their study that only 12% of
those who began treatment remained in the program beyond six
months.  In a study conducted by Tennant and his colleagues,
only 16% of the program participants completed the program
successfully. D’Ippoliti and his colleagues conducted a study on
treatment retention in Italy and found that after one year, the
retention rate among 1,503 heroin users using naltrexone was
18%.40 Some of the results of the SNAP program showed better
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41. Robert Greenstein et al., supra note 24 at 677.  See also, Robert
Greenstein et al., supra note 38 at 27.  See supra note 31 to the
contrary.
42. See, Jonathan Rabinowitz, et al., Compliance to Naltrexone
Treatment After Ultra-Rapid Opiate Detoxification: An Open Label
Naturalistic Study, 47 DRUG & ALCOHOL DEPENDENCE, Aug. 1997,
at 77; Domingos Neto et al., Sequential Combined Treatment of
Heroin Addicted Patients in Portugal with Naltrexone and Family
Therapy, 3 EUR. ADDICTION RES., July 1997, at 138; Philip Robson
& Margaret Bruce, A Comparison of “Visible” and “Invisible” Users
of Amphetamine, Cocaine and Heroin: Two Distinct Populations, 92
ADDICTION, 1729 (1997); Michael Gossop et al., Severity of
Dependence and Route of Administration of Heroin, Cocaine and
Amphetamines, 87 BRIT. J. ADDICTION, 1527 (1992); and Arnold
Washton et al., Successful Use of Naltrexone in Addicted Physicians
and Business Executives, 4 ADVANCES IN ALCOHOL AND SUBSTANCE
ABUSE 89 (1984).  See also, infra note 41.  For the assertion that
there is a distinction between compulsive/addictive users of
heroin and nonaddictive, long-term moderate users of heroin see,
Wayne M. Harding, Controlled Opiate Use: Fact or Artifact?, 3
ADVANCES IN ALCOHOL & SUBSTANCE ABUSE, Fall-Winter 1983, at
105.
43. See, Augusta Roth et al., Naltrexone Plus Group Therapy for
Treatment of Opiate-Abusing Health Care Professionals, 14 J.
SUBSTANCE ABUSE TREATMENT, 19 (1997); Walter Ling & Donald
Wesson, Naltrexone Treatment for Addicted Health Care
Professionals: A Collaborative Private Practice Experience, 9 J.
CLINICAL PSYCHIATRY, Sept. 1984, at 46; Arnold Washton et al.,
Naltrexone in Addicted Business Executives and Physicians, 9 J.
CLINICAL PSYCHIATRY, Sept. 1984, at 39; John Gonzalez & Rex
Brogden, Naltrexone: A Review of Its Pharmacodynamic and
Pharmacokinetic Properties and Therapeutic Efficacy in the
Management of Opioid Dependence, 35 DRUGS, Mar. 1988, at 192;
Richard Resnick et al., supra note 23.  See also, OFF. NAT’L DRUG
CONTROL POLICY, WHITE PAPER: TREATMENT PROTOCOL
EFFECTIVENESS STUDY (1996); A. Thomas McLellan, Patient
Characteristics Associated with Outcome, in RESEARCH ON
TREATMENT OF NARCOTIC ADDICTION 500 (James Cooper ed., 1983).  
44. See, Richard Resnick et al., supra note 25. See also, Richard
Resnick et al., A Cyclazocine Typology in Opiate Dependence, 126
AM. J. PSYCHIATRY, 1256; Richard Resnick & Arnold Washton,
Clinical Outcome with Naltrexone: Predictor Variables and Follow-
up Status in Detoxified Heroin Addicts, 311 ANNALS NEW YORK
ACAD. SCI., 241 (1978).
results than some of the work in the literature.  The research
literature suggests that patients in a naltrexone program will
“test naltrexone’s opiate blockade at least once during treat-
ment.”41 The results of this program show that the patient on
naltrexone may not test the blocking effect of the drug.  The
large majority of patients, 75%, did not test positive for any
drugs during their participation in the program.  
The program achieved other measures of drug treatment
success noted in the literature, including employment status
change and post-program arrest history.  The majority of SNAP
program participants left the program employed, regardless of
their discharge status.  Those who were employed at time of
discharge had a higher rate of successful treatment than those
who were not employed.  Additionally, the percentage of those
who were employed and who failed the treatment program was
less than those who were unemployed and failed the treatment
program.  
Other observations about drug addiction in the literature
were confirmed, specifically that “softer” drugs serve as an
introduction to “harder” drugs and that drug use starts in the
early years of adolescence.   Alcohol and marijuana proved to
be the two introduction drugs to the SNAP patients.  Heroin
proved to be a distant third.  Drug use of SNAP participants
began in their teen years.  A majority of the SNAP patients
were between 13 and 18 when they first began using drugs.
These results support the general belief that drug use begins in
the early years of the addict’s life, and if a person can remain
drug free through these early years the chances of becoming an
addict decrease.  
POLICY IMPLICATIONS FOR THE JUDICIARY 
ON THE DESIGN AND UTILITY OF DRUG 
TREATMENT PROGRAMS
I. The judiciary should assess what type of addict is
before the bench before ordering the addict to a
drug treatment program.
If the case involves a
non-professional, high-
addiction-level, street
addict, the likelihood of
successful completion
ranges between a low of
12% to a high of 20%.
The court should review
the type of drug treat-
ment programs that are
available and make sure
that the program is designed to handle the type of
addict the court is dealing with.
There are different types of heroin addicts with dif-
ferent expectancy rates of successful treatment com-
pletion.42 Treatment programs are more successful
with addicts who have a stable family structure; are
married to a nonaddicted mate; are highly motivated to
stop using heroin; have good jobs; have minimal anti-
social behavior; have low drug craving/addiction; or
have high professional, social, or economic status.43
Programs with addicts who use heroin as a “self-med-
ication” have a higher rate of program discontinuation
or failure.44
II. Assessment of success of drug treatment programs
should be made using multiple measures, including
abstinence rates, improvement in employment sta-
tus, success in therapy treatment, reaching of social
goals, positive behavior changes, and the level of
involvement in criminal activity, rather than on
retention rates alone. The court should not assume
that failure to complete the program is analogous to
failure.









45. George DeLeon & Nancy Jainchill, Circumstances, Motivation,
Readiness and Suitability as Correlates of Treatment Tenure, 18 J.
PSYCHOACTIVE DRUGS, 203 (1986). 
It has been asserted that treatment programs are destined for
failure because they don’t consider the multifaceted factors of why
the treatment is being offered, the difference between treatment
and therapy, why an addict is seeking treatment, who is offering
the treatment, and why the addict has an addiction.  Additionally,
the lack of specific and meaningful goal setting for the individual
addict, the lack of specific diagnosis of the individual addict, the
confusion of goals to help the addict become an effective patient
with goals to make the patient a better citizen by improving his or
her lifestyle, and confusing different theories of therapy and treat-
ment modalities all help to create program design problems that
lead to failure.  See, Stanley Einstein, Factors Initiating/Affecting
the Treatment of Drug Use and the Drug User, 15 INT’L J. ADDICTIONS
773 (1980).
46. Nachman Ben-Yehuda, Success and Failure in Rehabilitation: The
Case of Methadone Maintenance, 9 AM. J. COMMUNITY PSYCHOL., 83
(1981).  It has also been observed that since treatment programs
generally are not evaluated using random selection of patients
and control groups and established baseline measurements and
have reliability and validity limitations, the fact of high attrition
rates should not be the sole assessment of success.  William Berg,
Evaluation of Community-Based Drug Abuse Treatment Programs: A
Review of the Literature, in THE ADDICTIVE PROCESS: EFFECTIVE
SOCIAL WORK APPROACHES 81 (E. Freeman ed., 1992). 
47. William Berg, supra note 46 at 84.
48. Id.
48. Nachman Ben-Yehuda, supra note 46 at 85.
50. Id. at 86.
51. George DeLeon & Nancy Jainchill, supra note 45.  For two theo-
ries on the readiness to change and its impact on behavior change
see, James Prochaska et al., The Transtheoretical Model of Behavior
Change, in THE HANDBOOK OF HEALTH BEHAVIOR CHANGE 59 (Sally
Shumaker et al. ed., 2nd ed., 1998), and Neil Grunberg et al.,
Biological Obstacles to Adoption and Maintenance of Health-
Promoting Behaviors, in THE HANDBOOK OF HEALTH BEHAVIOR
CHANGE 269 (Sally Shumaker et al. ed., 2nd ed., 1998). 
52. Nachman Ben-Yehuda, supra note 46.  The future-oriented indi-
vidual looks to the future and makes plans to make his or her life
better in the future.  Decisions are meant to generate change as
supposed to a past-oriented person who lives from moment to
moment, who is resistant to change or unwilling to take account
of behavior and make decisions that produce benefits in the
future. Id. at 88, 97.  “Future-oriented patients apparently benefit
most from their therapeutic experience in [drug treatment] pro-
grams.” Id. at 97.  This classification as either past or future ori-
ented can be helpful in the designing and the selection of clients
for a potential drug treatment program.  “Upon admission . . .
patients could be classified . . . as to the behavior expected of
them while [in] the program.  This information could potentially
help clinical and administrative personnel working with drug-
abuse to better deal with their patients, construct differential
treatment plans for them, and assess success more meaningfully.”
Id. at 97.
53. George DeLeon & Nancy Jainchill, supra note 45. A positive moti-
vation is “ a desire to forge a new lifestyle; a belief that one can be
successful and have the good things in life; or a desire for per-
sonal growth, to be a better person . . . as well as to have health-
ier relationships.” Id. at 203.
54. James Prochaska et al., supra note 51.  In the preparation stage
“people are intending to take action in the immediate future, usu-
ally measured as during the next month.  These individuals have
a plan of action. . . . These are the people we should recruit for
. . . action-oriented programs.” Id at 61.
High dropout rates are “the
rule for all drug treatment
modalities as for treatment of
other psychological prob-
lems.”45 While the “retention
rate” has been the most used
and widespread criterion for
success, this criterion alone is
unreliable for assessing the
success of a treatment pro-
gram or the individual client
in treatment because it does
not take into account changes
in the behavior and lifestyle of
the individual.46
One of the limitations to
the retention rate criteria is
that it does not take into
account the factor of self-
selection.47 Use of retention
rates as a determination of
success is vulnerable to selection bias because those who suc-
cessfully stay in a treatment program do so because the pro-
gram expels them or they choose to remain in the program.
Thus, the “success” or “failure” of the program based on reten-
tion is artificially inflated or deflated by those who are removed
from the program either by the participants’ choice or by the
program.  Selection bias produces an outcome, i.e., success or
failure that can be explained as function of individual differ-
ences among the patients and not the treatment program.
Although, the “single most important predictor of success
[is] the length of stay in treatment,”48 “the so-called retention
rate . . . simply measures the length of time an addict stays in
a program,”49 not the change in the addict due to the program.
It has also been noted that retention rates can be associated
with factors outside of the program, including environmental
support for drug addiction, personality characteristics of the
addict, employment status, status and health of the addicts’
family, psychological status of the addict, criminal history,50
the readiness of the addict to change,51 and multiple drug use
history.  
III. Research shows that more than 80% of the clients
in a drug treatment program drop out from the pro-
gram during a first attempt at drug treatment.  The
court should determine if the addict is at a point in
his or her addiction that allows for successful
treatment.
Research on program treatment dropouts as well as theory
on behavior change notes that treatment programs work with
patients who are future oriented,52 have a positive motivation
to change,53 and are at a stage in their addiction when prepa-
ration for change54 is achieved.  The future-oriented addict has
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Addictive and Mental Disorders, 12 ARCHIVES PSYCHIATRIC NURSING,
Apr. 1998, at 71.
56. Id.
57. H. Lawrence Ross et al., Retention in Substance Abuse Treatment:
Role of Psychiatric Symptom Severity, 6 AM. J. ADDICTION 293
(1997).
58. Jennifer Tidey et al., Psychiatric Symptom Severity in Cocaine-
Dependent Outpatients: Demographics, Drug Use Characteristics
and Treatment Outcome, 50 DRUG & ALCOHOL DEPENDENCE, Mar.
1998, at 9. 
59. Joan Russo et al., Psychiatric Status, Quality of Life, and Level of
Care as Predictors of Outcomes of Acute Inpatient Treatment, 48
PSYCHIATRIC SERVICE 1427 (1997).  For research on addressing the
emotional and spiritual factors that can affect heroin treatment
success or failure see Karen Miotto et al., Overdose, Suicide
Attempts and Death Among a Cohort of Naltrexone-Treated Opioid
Addicts, 45 DRUG & ALCOHOL DEPENDENCE Apr. 1997, at 131, and
Leslie Green, et al., Stories of Spiritual Awakening: The Nature of
Spirituality in Recovery, 15 J. SUBSTANCE ABUSE TREATMENT, 325.
60. Rao Rapaka & Heinz Sorer, Introduction, in DISCOVERY OF NOVEL
OPIOID MEDICATIONS (Nat’l. Inst. on Drug Abuse Res. Monograph
decided to make a change and end his or her addiction.  The
addict is positively motivated because the change is self-
desired—the addict wants a better life.  The addict is prepared
to change and demonstrates this preparation by the formation
of a plan to end the addiction.  The addict enters the program
having decided to enter a treatment program with the desire
and expectation to successfully complete it, as compared to
entering the program to avoid incarceration. 
If the program is servicing addicts who have not reached the
point of having a future-oriented, positively motivated, pre-
pared mental state to make a change in their lives (i.e., end
their heroin addiction) success rates will be low regardless of
the value of the program. 
IV. The presence of psychological dysfunction on
potential clients can affect retention and successful
completion rates.   The court should determine
whether the treatment modality can accommodate
clients who have psychological problems.
Treatment programs need to be designed to address
the individual addict and quality-of-life issues that
the addict is experiencing, along with the addiction
to the drug itself.  
Many of those who enter drug treatment programs have
moderate to severe mental illness.55 More significant is the fact
that only about half of those addicts who have a mental illness
receive treatment for the mental illness and the drug addiction
together.56 The presence of mental illness and dropout rates
have been shown to be associated.57 Research has also found
that mental illness can affect the ability to function and how
drugs impact the individual.58 Programs that address both drug
addiction and mental illness should design treatment modali-
ties to take into account the importance of the client’s quality of
life. Recent research has noted that the patients’ quality of life
(family support, employment, positive self-image, etc.) can pre-
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dict successful treatment indepen-
dent of other factors, including the
psychiatric status of the client.59
V. Drug addiction is not a prob-
lem in which the addiction
to a specific drug is the only
focus of attention.  Drug
addiction is usually one
member of a family of issues
within the life of the addict. 
The nature of addiction has been described as a state in
which the addict (1) has a persistent regular use of a drug; (2)
attempts to stop such use leads to significant and painful with-
drawal symptoms; (3) continues to use the addictive drug
despite damaging physical or psychological problems, or both;
(4) engages in compulsive drug-seeking behavior; and (5)
needs a constant increasing level of dosage of the drug to get
“high.”60
Treatment programs should implement program modalities
in the light of recent research that has observed that (1) drug
use occurs within a broader family of social and psychological
problems, (2) cognitive-behavioral abilities are fundamentally
psychological in nature, (3) the motivation to change is a cog-
nitive-behavioral process, and (4) the skills and the relation-
ship between the client and the individual counselor has an
impact on final outcome.61
VI. The court should consider if the drug treatment pro-
gram design encompasses the biochemical as well as
the cognitive-behavioral aspects of addiction when
designing drug addiction treatment modalities. 
Virtually “all drugs . . . have common effects, either directly
or indirectly, on a single pathway deep within the brain.”62 In
# 147) (Roa Rapaka & Heinz Sorer eds., 1995), at v. 
61. William Miller & Sandra Brown, Why Psychologists Should Treat
Alcohol and Drug Problems, 52 AM. PSYCHOL. 1269 (1997).  James
Inciardi explains:
drug abuse as overdetermined behavior.  That is, physical
dependence is secondary to the wide range of influences
that instigate and regulate drug-taking and drug seeking
behaviors.  In the vast majority of drug offenders, there are
cognitive problems; psychological dysfunction is common;
thinking may be unrealistic or disorganized; values are mis-
shapen, and frequently, there are deficits in education and
employment skills.  [D]rug use is a response to a series of
social and psychological disturbances.
James Inciardi, “Drug Treatment in Prisons,” presentation at the
Summit on U.S. Drug Policy, U.S. House of Representatives,
Committee on the Judiciary, Washington, D.C. (May 7, 1993), at
3–4.  See also, Robert Hooper et al., Treatment Techniques in
Corrections-Based Therapeutic Communities, 73 PRISON J.,
Sept./Dec., 1993, at 290.
62. Alan Leshner, Addiction Is a Brain Disease, and It Matters, 278
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64. SHAMSHA, supra note 21 at 27.
65. Id.
66. Id.
67. Id. at 28.  See also, Robert Swift, Medications and Alcohol Craving,
23 ALCOHOL RES. & HEALTH: J. NAT’L. INST. ALCOHOL ABUSE &
ALCOHOLISM, 207 (1999). See also infra notes 69 and 71 for stud-
ies dealing with craving and the biochemical dynamics of drug
addiction.
68. SHAMSHA, supra note 21 at 27.  See also, infra notes 69 and 71.
69. See Neuroscience:  Pathways of Addiction, 21 ALCOHOL HEALTH &
RES. WORLD: J. NAT’L INST. ALCOHOL ABUSE & ALCOHOLISM (1997)
for a series of articles on the biochemistry of addiction. 
70. See, supra notes 27–32 and accompanying text.  
71. For general discussion on craving and drug use see, Raymond
Anton, What Is Craving? Models and Implication for Treatment, 23
ALCOHOL HEALTH & RES. WORLD: J. NAT’L INST. ALCOHOL ABUSE &
ALCOHOLISM, 165 (1999); Stephen Tiffany, Cognitive Concepts of
Craving, 23 ALCOHOL HEALTH & RES. WORLD: J. NAT’L INST.
ALCOHOL ABUSE & ALCOHOLISM, 215 (1999); and Mary Jo Breiner
et al., Approaching Avoidance: A Step Essential to the Understanding
of Craving, 23 ALCOHOL HEALTH & RES. WORLD: J. NAT’L INST.
ALCOHOL ABUSE & ALCOHOLISM 197 (1999).
regard to the effect of heroin on
the brain, research has found that
heroin focuses on the opioid
receptors of the brain.  As previ-
ously noted63 the pleasure from
opiates “can be more powerfully
rewarding than that produced by
natural reinforcers.”64 This
assessment is significant in the
study of how and why drug
addiction is developed and main-
tained through positive and neg-
ative reinforcement.
In studies dealing with positive and negative reinforcement,
it is believed that if pleasure responses can be secured artifi-
cially a person will choose the artificial stimulation even over
natural positive stimulation such as food or sex.
[The] process in which a pleasure-inducing
action becomes repetitive is called positive rein-
forcement. Conversely, abrupt discontinuation of
alcohol, opiates, and other psychoactive drugs fol-
lowing chronic use . . . results in discomfort and
craving. The motivation to use a substance in order
to avoid discomfort is called negative reinforcement.
Positive reinforcement is believed to be controlled
by various neurotransmitter systems, whereas nega-
tive reinforcement is believed to be the result of
adaptations produced by chronic use within the
same neurotransmitter systems.65
The use of heroin creates both positive and negative rein-
forcement through its processing within the brain.  The heroin
acts as an exogenous opiate within the brain and acts as a neu-
rotransmitter for pleasure within the brain.  The heroin pro-
duces a stronger pleasure reaction than endogenous opioids
(endorphins and enkephalins). 
The chronic use of exogenous opiates within the pleasure-
seeking system drives the need for the exogenous opiates, and
the opioid receptors are now only stimulated by the exogenous
opiates, rather than by natural pleasure stimuli.  “Natural rein-
forcers such as food, drink, and sex [which] activate [pleasure]
pathways in the brain [are replaced by the exogenous opiates]
as surrogates of the natural reinforcers.”66 It is also believed
that the use of these opiates and the negative reinforcement
they produce (the need for the opiates to avoid pain due to
lack of presence of the opiate) are aided by other natural
occurring neurotransmitters in the brain, such as dopamine
and serotonin.  Dopamine produces immediate feelings of
pleasure and elation that reinforce certain behaviors, such as
eating or sex, and motivates repetition of these activities.67
Dopamine is believed to be produced with the use of opiates.
“Serotonin is associated with the reinforcing effects of many
abused drugs through its mood regulating and anxiety reduc-
ing effects.  Low levels of serotonin are associated with depres-
sion and anxiety.”68 The lack of stimulation by opioid recep-
tors is believed to be a cause for low levels of dopamine and
serotonin. The lack of these two chemicals is thought to pro-
duce depression, which in turn produces the craving for the
heroin to relieve feelings of depression and to restore feeling
pleasure or at least feeling “normal.”
The cycle of addiction and compulsive and impulsive drug
use is compounded by biochemical change within the brain69
and cognitive-behavioral cues.  The cycle of addiction is
started by positive reinforcement and then driven by negative
reinforcement.  Heroin produces a strong pleasure effect, and
cognitively, the user decides to use the drug again to receive
the same pleasurable effect.  The opioid receptors of the brain
become addicted to the presence of the heroin and then require
the heroin stimulation continuously.  Here is where negative
reinforcement takes control.  The user no longer takes the
heroin to feel pleasure, but to feel “normal.”  The purpose in
taking the heroin is to avoid painful sensations not to enjoy
pleasurable sensations.  During drug treatment the addict will
desire to take heroin on two levels.  Impulsive use will occur
due to cues in the environment or by memories of taking the
drug.  The addict takes the drug almost without thinking about
the consequences.  Compulsive (craving) drug use occurs due
to the addict obsessing over the pleasure gained by the drug.
The addict thinks about the drug, and the thoughts drive the
addicts to relapse.  
The use of naltrexone addresses the results of heroin use
due to impulsive and compulsive behavior.70 But the issue
treatment programs need to contend with is the cognitive
behavior of addicts in that they decide that life without heroin
is not desirable and simply choose to stop taking the naltrex-
one so that they can enjoy the pleasure of the heroin.  The
treatment therapy must create new cognitive pathways within
the brain to allow for controlling the cravings71 for the heroin
and new behavior patterns to deal with the social factors of
their lives.  Since human beings have the ability to cognitively
choose to do or not do something, drug treatment programs
need to focus on how the individual addict handles life stres-
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72. Alan Leshner, supra note 62 at 46. See also, George Koob et al.,
Neuroscience of Addiction, 21 NEURON 467 (1998).  Some recent
research has asserted that addiction can be traced to genetics, see
Thomas Kosten, Addiction as a Brain Disease, 155 AM. J.
PSYCHIATRY 711 (1997).
73. Alan Leshner, supra note 62 at 46.
74. Charles O’Brien, Progress in the Science of Addiction, 154 AM. J.
PSYCHIATRY 1195, 1195 (1997).  O’Brien asserted that
Drug exposures . . . paired with environmental cues (per-
sons, places, things) . . . acquire the ability to activate the
same or complementary brain circuits even in the absence
of the drug.  Id. Drug-related cues alone have [been shown
to produce] increases in limbic blood flow in formerly
dependent cocaine users . . . . Drug cues have also produced
increases in the metabolism of specific brain areas. Id. at
1196. 
This explains why addiction is considered to be a chronic disease.
Although the use of drugs has ended, pathways and brain chem-
istry have been altered so as to produce the effects of the “disease”
although the agent causing the disease is no longer present.
Although this chemical analysis may be true, the choice of
whether to indulge in an impulse or compulsive need (chemically
created or not) is not destroyed. One still chooses to indulge a
desire and one chooses to frequent an area that provides those
cues of addiction.  
75. Aviel Goodman, Science of Addiction (Letter to the Editor), 155
AM. J. PSYCHIATRY 1642, 1642 (1998).  Goodman goes on to say
the following:
I would describe addiction as a chronic condition that
develops through a process that involves complex interac-
tions over time between genetic and environmental factors.
More specifically, I would propose that two sets of determi-
nants are involved in the development of an addictive dis-
order: 1) those that concern underlying neurobiological
abnormalities that are shared by all addictive disorders and
2) those that relate to the selection of a particular substance
as the one that is preferred for addictive use. I would add
that each set includes both genetic and environmental fac-
tors. Environmental factors in the development of the
underlying neurobiological abnormalities include deficien-
cies in the child’s caregiving environment during the first
years of life, when the maturing brain is most sensitive to
external influences and depends on particular qualities of
interchange with the caregiving environment for healthy
development. Genetic factors in selection include geneti-
cally based variations in 1) the sensitivity of the reward sys-
tem to different substances, 2) the body’s sensitivity to
immediate aversive consequences of using a substance
(such as flushing or standing ataxia after ingestion of alco-
hol), and 3) the intensity of the individual’s sensitivity to
various painful effects [which are] associated with . . . neg-
ative reinforcement.  
See, Bruce Lawford et al., The D(2) Dopamine Receptor A (1) allele
and Opioid Dependence: Association with Heroin Use and Response
to Methadone Treatment, 96 AM. J. MED. GENETICS:
NEUROPSYCHIATRIC GENETICS 592 (2000), for research showing that
heroin addicts that have a certain type of dopamine receptor are
more likely to drop out or fail a methadone treatment program
than those without this variation. The research noted that there
were significantly more heroin addicts with this variation (TaqI
A(1) allele of the D(2) dopamine receptor) in a group of addicts
that had poor treatment outcomes compared to those who had
successful treatment outcomes.  The researchers also found that
19% of the heroin addicts had this variation compared to 4.6% of
a control group of people free from drug and alcohol use and free
from a family history of alcohol and drug use.
76. Gene Heyman, On the Science of Substance Abuse (Editorial), 278
SCIENCE, 15 (1997).
77. Id. at 15.
sors and train the addict to resort to socially positive alterna-
tives to reduce stress, rather than resort to the use of heroin. 
VII. The biochemical and cognitive-behavioral aspects
of drug addiction present the criminal justice sys-
tem with political as well as social policy issues.
The criminal justice system needs to contend with
the implications of the fact that drug addicts have
altered brain chemistry, while maintaining its
inherent purpose of focusing on individual
accountability and responsibility. Conversely, drug
treatment designers and drug addiction scientists
must contend with the fact that personal responsi-
bility and accountability will always be a demand
of policy makers and the public regardless of the
science of addiction.
Research on addiction shows that prolonged drug use
“causes pervasive changes in the brain [and] the addicted
brain is distinctly different from the non addicted brain” and
this fact leads to the conclusion that on a general policy level
“the addicted individual must be dealt with as if he or she is in
a different brain state.”72 In other words, treat drug addicts as
those whose minds have been “altered fundamentally by
drugs.”73 Although the literature is settled on the fact that
addiction causes changes in the
brain, there is some debate on the
cause of addiction.  For example,
O’Brien defined addiction as acts
of  “a chronic disease produced
by thousands of exposures to
drugs.  Each drug taking episode
activates specific brain struc-
tures, leaving a memory trace
that persists long after the drug
has disappeared from the body.”74
Goodman explains that addiction
is not formed by repeated use of a
drug, but develops through a
combination of environmental
and genetic characteristics.75
Heyman, while agreeing, “changes in brain function alter
voluntary behavior,” notes that addiction is still a behavior of
which social and economic costs can persuade addicts to end
their addiction.76 Heyman asserts that there are two types of
addicts, those who take drugs voluntarily and those who do so
involuntarily.  The former can be persuaded cognitively but the
latter will “not be persuaded by costs and incentives to stop
using them.”77 O’Brien asserts that three factors should be
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addicts:  (1) the availability of
the drug and its cost and purity;
(2) the genetic predisposition
of the addict; and (3) the
applicable social and environ-
mental pressures on the addict
to continue or stop drug use.78
Although neuroscientists are
convinced that addiction is a
biological issue involving brain
damage, “the more common
view is that drug addicts are
weak . . . unwilling to lead
moral lives and to control their
behavior and gratifications.”79
Although the point of drug
addiction and personal respon-
sibility for addiction has been
belittled in some of the litera-
ture, there is value in the com-
mon belief that human beings think and thus can control their
behavior.  The ability to be responsible for an addiction accom-
panies the power to end addiction.  The mere fact that one has
damaged his or her brain and formed neuropathways for cer-
tain stimuli does not mean that the ability to choose has been
destroyed.  The fact that human beings have the ability to
think, learn (form new neuropathways), and choose between
behaviors seems to be acknowledged as an afterthought by
some of the literature on addiction.  The political (used here to
mean philosophical) view that behavior is a cognitively con-
trolled activity that is at least equal in the cause and mainte-
nance of addictive behavior needs to be considered by treat-
ment program designers and neuroscientists.  Those who make
political policy may not be aware or care about the science of
addiction, especially if the idea of personal responsibility is not
reflected in theories of addiction.  For example, Congress has
recently restricted social security payments and other social
benefits from those who have drug addictions.80 Similarly, the
judiciary should make sure that a proposed drug treatment
program modality includes personal responsibility and behav-
ior modification as one of the tools to address drug addiction.
Both the science of addiction and personal responsibility
add to the understanding of addiction and addiction treatment.
Moral responsibility aside, drug addiction brings serious and
chronic physical and social consequences.81 As noted by
Heyman, three factors should be kept in mind when trying to
understand addiction: “[1] drug use in addicts can be altered
by the proper arrangements of costs and benefits, [2] addictive
drugs reduce options but do not eliminate choice, and [3] the
biology of addiction is the biology of voluntary behavior.”82
Arthur H. Garrison is the criminal justice plan-
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uation at the Delaware Criminal Justice
Council. He is a member of the Society of Police
and Criminal Psychology.  Garrison has pub-
lished articles in various journals, including the
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Confinement, Journal of Police and Criminal
Psychology, Police Studies, Issues in Child Abuse Accusations,
American Journal of Trial Advocacy, and Juvenile and Family
Court Journal.  Garrison received his B.S. (1990) from Kutztown
University of Pennsylvania and his M.S. (1995) from West
Chester University of Pennsylvania.  
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should make









one of the tools
to address drug
addiction.
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